论文部分内容阅读
目的观察聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎的临床疗效及安全性。方法共收集我院68例HBeAg阳性慢性乙型肝炎患者,随机分为A、B两组各34例分别给予聚乙二醇干扰素α-2a和普通干扰素α-2a治疗,于治疗24周和48周时,检测两组HBV血清学标志物及血清ALT变化,并记录不良反应。结果治疗24周、48周时,A组血清HBeAg阴转率、ALT复常率均明显高于B组,差异有统计学意义(P<0.05)。结论聚乙二醇干扰素α-2a治疗慢性乙型肝炎疗效优于普通干扰素,且用药简单、方便,从而改善患者的依从性,以确保其疗效。
Objective To observe the clinical efficacy and safety of pegylated interferon α-2a in the treatment of HBeAg-positive chronic hepatitis B patients. Methods A total of 68 patients with HBeAg-positive chronic hepatitis B in our hospital were randomly divided into A and B groups of 34 patients treated with peginterferon alfa-2a and interferon alpha-2a respectively. After treatment for 24 weeks At 48 weeks, HBV serological markers and serum ALT levels were detected in both groups, and adverse reactions were recorded. Results At 24 and 48 weeks of treatment, the serum HBeAg negative conversion rate and ALT abnormality rate in group A were significantly higher than those in group B (P <0.05). Conclusions Pegylated interferon α-2a is more effective than common interferon in the treatment of chronic hepatitis B, and the medication is simple and convenient, so as to improve patient compliance and ensure its efficacy.